SecBot SecBot
8-K ·Filed May 8, 2026

BIOA

BioAge Labs, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-213472
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The EPS beat and positive clinical data are likely to drive near-term upside. The key catalyst is the Phase 2 proof-of-concept data for BGE-102 in cardiovascular risk, expected by year-end 2026. Monitor initiation of trials in mid-2026 and any partnership updates.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$17.99
T+0 close · May 8, 2026 · via day close
Latest settled
−37.74%
T+60 · $11.20
Vs SPY
−42.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $17.99entry
  2. T+1 · 6mo ago +0.94%α +0.71% · $18.16
  3. T+5 · 6mo ago +4.03%α +2.57% · $18.72
  4. T+20 · 5mo ago −12.73%α −12.75% · $15.70
  5. T+60 · 3mo ago −37.74%α −42.58% · $11.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $-0.52 vs consensus $-0.71 (26.8% beat). Net loss widened to $22.3M from $12.9M, driven by increased R&D spending on BGE-102 and APJ programs. The company highlighted positive Phase 1 data for BGE-102 and plans to initiate Phase 2 trials in mid-2026, with a strong cash position of $384.9M.

Key Financial Metrics

EPS
−$0.52
est −$0.71 · +26.8%
Revenue
$2.8M
+91.0% YoY
Rating
beat

Key Facts

  • Collaboration revenue of $2.8 million in Q1 2026 vs $1.5 million in Q1 2025
  • Net loss of $22.3 million ($0.52 per share) vs consensus estimates of $-0.71 per share
  • Positive topline Phase 1 data for BGE-102 (oral NLRP3 inhibitor) showing 86% median hsCRP reduction
  • Phase 2 dose-ranging trial in cardiovascular risk planned for mid-2026, data expected by year-end
  • Phase 1b/2a trial in diabetic macular edema also planned for mid-2026
  • Cash, cash equivalents, and marketable securities of $384.9 million, sufficient through 2029

Financial Impact

Net loss per share beat consensus by 26.8% ($-0.52 vs $-0.71); collaboration revenue more than doubled YoY to $2.8M

epsrevenuenet losscash position

Risk Factors

  • Clinical trial failure or delays for BGE-102
  • Rising operating losses and cash burn
  • No approved products or recurring revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-213472
Document: bioa-20260508.htm0001193125-26-213472
Document: 0001193125-26-213472-index-headers.html0001193125-26-213472
Document: 0001193125-26-213472-index.html0001193125-26-213472
Document: 0001193125-26-213472.txt0001193125-26-213472
8-K Data (Synthetic)0001193125-26-213472

Track record

11 reports on BIOA

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
  4. Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
  5. May 8, 202627w ago 8-K Bullish 7/10 Viewing Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
  6. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
  7. Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
  8. Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
  9. Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
  10. Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (11h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026